Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

FirstWord Pharma
firstwordpharma.com > story > 7984983

WCLC26: GSK's ris-rez cuts death risk 54% in China Phase III lung cancer trial

21+ hour, 40+ min ago   (16+ words) FirstWord Pharma...

FirstWord PHARMA
firstwordpharma.com > story > 7972418

Animal data trigger enrollment pause in Biohaven's epilepsy study

3+ day, 17+ hour ago   (11+ words) FirstWord PHARMA...

FirstWord Pharma
firstwordpharma.com > story > 7963969

Inhibrx touts HNSCC subgroup data, eyes accelerated pathway for OX40 agonist

5+ day, 13+ hour ago   (13+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7960102

Roivant's pulmonary hypertension drug mosliciguat scores mid-stage win

6+ day, 2+ hour ago   (10+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7959810

Novartis??? Avidity-sourced del-desiran stumbles in Phase III myotonic dystrophy study

6+ day, 5+ hour ago   (12+ words) Novartis’ Avidity-sourced del-desiran stumbles in Phase III myotonic dystrophy study FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7957440

Novo's hopes for ziltivekimab dwindle as two heart failure studies stopped early

1+ week, 3+ hour ago   (14+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7952422

Novartis' pelacarsen fails critical cardiovascular test

1+ week, 2+ day ago   (8+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7941882

Owkin lands third major pharma partner in AI deal with Boehringer Ingelheim

1+ week, 4+ day ago   (14+ words) FirstWord Pharma...

FirstWord Pharma
firstwordpharma.com > story > 7937682

Roche nabs tri-specific antibody from Simcere in $1.5B deal

1+ week, 5+ day ago   (11+ words) FirstWord Pharma...

firstwordpharma.com
firstwordpharma.com > story > 7936269

Novartis' Rhapsido delivers dual Phase III wins in relapsing MS

1+ week, 5+ day ago   (11+ words) firstwordpharma.com...